Skip to main content
NeoImmuneTech, Inc. logo

NeoImmuneTech, Inc. — Investor Relations & Filings

Ticker · 950220 ISIN · KR8840140006 LEI · 254900489QR747TPTT13 KO Professional, scientific and technical activities
Open in API
Filings indexed 221 across all filing types
Latest filing 2025-08-21 Director's Dealing
Country US United States of America
Listing KO 950220

About NeoImmuneTech, Inc.

https://www.neoimmunetech.com/en

NeoImmuneTech, Inc. is a clinical-stage, T cell-focused biopharmaceutical company dedicated to the development of novel immuno-therapeutics. The company's lead asset is NT-I7 (efineptakin alfa), a long-acting human interleukin-7 (IL-7) fusion protein designed to amplify and reinvigorate T cells. This core technology aims to enhance the immune system's ability to eliminate cancer cells and pathogens. NT-I7 is being developed as a foundational immuno-oncology therapy for use in combination with other cancer treatments, such as checkpoint inhibitors, as well as for applications in infectious diseases. The company's research is focused on leveraging T cell amplification to address a wide range of challenging diseases.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard regulatory filing in South Korea (DART system) used by corporate insiders to disclose changes in their shareholdings. This corresponds to the 'Director's Dealing' category, which covers insider trades and changes in ownership by company directors and executives.
2025-08-21 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Major Shareholding Notification Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean financial authorities. This type of filing is a mandatory disclosure by insiders or major shareholders regarding changes in their shareholdings or related securities. In the context of the provided categories, this falls under 'Director's Dealing' (DIRS), which covers insider transactions and changes in ownership by major shareholders.
2025-08-20 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is titled '주식등의 대량보유상황보고서' (Report on Large Shareholding of Stocks, etc.), which is a standard regulatory filing in South Korea under the Capital Markets Act (Article 147). It details changes in shareholding percentages, specifically involving a major shareholder (Genexine, Inc.) and their relationship with the issuer (NeoImmuneTech). This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2025-08-20 Korean
[기재정정]증권신고서(증권예탁증권)
Capital/Financing Update Classification · 95% confidence The document is a '증권신고서(증권예탁증권) 정정신고' (Amendment to Securities Registration Statement) filed by NeoImmuneTech. It details specific corrections made to a previously filed securities registration statement, including updates to business risks, intellectual property status, and research personnel data. In the context of Korean financial filings (DART), a '증권신고서' is a regulatory filing related to the issuance of securities, which falls under the 'Regulatory Filings' category as it is a formal disclosure document required by the regulator.
2025-08-20 Korean
투자판단관련주요경영사항(임상시험결과) (NIT112 (거대 B세포 림프종, NTI7 및 CART 치료제 병용 요법) 임상 1b상 임상시험결과보고서(CSR) 수령)
Legal Proceedings Report Classification · 100% confidence The document is a formal regulatory disclosure filed by NeoImmuneTech regarding the receipt of a Clinical Study Report (CSR) for a Phase 1b clinical trial. It details the trial methodology, safety results, efficacy data (ORR), and future development plans. While it contains clinical trial results, it is structured as a 'Major Management Matter' (투자판단 관련 주요경영사항) filing, which is a standard regulatory disclosure format in the Korean market (KOSDAQ/KRX) for reporting material corporate events. Since it is a direct disclosure of clinical results rather than a mere announcement of a report's availability, and it does not fit into the other specific categories like 10-K or ER, it is classified as a Regulatory Filing (RNS).
2025-08-19 Korean
반기보고서 (2025.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-annual Report) for NeoImmuneTech, Inc., covering the period from January 1, 2025, to June 30, 2025. It contains detailed financial information, business operations, management discussions, and corporate governance details, which are characteristic of an interim financial report. It is not an announcement of a report (RPA) or a simple regulatory filing (RNS), as it contains substantive financial and operational data. H1 2025
2025-08-14 Korean

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.